EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 12 filers reported holding EVOKE PHARMA INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $3,000 | 0.0% | 1,285 | 0.0% | 0.00% | – |
| Q3 2016 | $3,000 | -40.0% | 1,285 | +76.5% | 0.00% | – |
| Q2 2016 | $5,000 | +150.0% | 728 | +48.9% | 0.00% | – |
| Q1 2016 | $2,000 | 0.0% | 489 | 0.0% | 0.00% | – |
| Q4 2015 | $2,000 | +100.0% | 489 | 0.0% | 0.00% | – |
| Q3 2015 | $1,000 | -66.7% | 489 | 0.0% | 0.00% | – |
| Q2 2015 | $3,000 | 0.0% | 489 | 0.0% | 0.00% | – |
| Q1 2015 | $3,000 | 0.0% | 489 | 0.0% | 0.00% | – |
| Q4 2014 | $3,000 | 0.0% | 489 | 0.0% | 0.00% | – |
| Q3 2014 | $3,000 | -25.0% | 489 | 0.0% | 0.00% | – |
| Q2 2014 | $4,000 | – | 489 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |